跳至主要内容
临床试验/NCT01243567
NCT01243567已完成4 期

Safety and Efficacy of Bimatoprost/Timolol Fixed Combination Versus Latanoprost in Patients With Open-Angle Glaucoma Who Have Never Been Treated

Allergan0 个研究点目标入组 81 人开始时间: 2010年6月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
Allergan
入组人数
81
主要终点
Change From Baseline in Average Intraocular Pressure (IOP)

研究概览

简要总结

This study will evaluate the safety and efficacy of bimatoprost/timolol fixed combination (GANfort®) versus latanoprost (Xalatan®) in patients with open-angle glaucoma who have never been previously treated and are at high risk for progression.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Investigator)

入排标准

年龄范围
18 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosis of primary open-angle glaucoma that has never been treated
  • Visual Acuity 20/60 or better in each eye

排除标准

  • Eye surgery within 3 months
  • Any refractive eye surgery
  • Contraindication to beta-adrenoceptor antagonist therapy (eg, chronic obstructive pulmonary disease [COPD], bronchial asthma, sinus bradycardia, heart block, history of severe myocardial infarction [heart attack])
  • Eye inflammation or eye infection within 3 months
  • Eye trauma within 6 months
  • Oral, injectable, or topical ophthalmic steroids within 21 days or anticipated use during study

研究组 & 干预措施

bimatoprost 0.03%/timolol 0.5% combination ophthalmic solution

Active Comparator

Bimatoprost 0.03%/timolol 0.5% combination ophthalmic solution (GANfort®) administered to each eye requiring treatment, once daily in the evening for 3 months.

干预措施: bimatoprost 0.03%/timolol 0.5% combination ophthalmic solution (Drug)

latanoprost 0.005% ophthalmic solution

Active Comparator

Latanoprost 0.005% ophthalmic solution (Xalatan®) administered to each eye requiring treatment, once daily in the evening for 3 months.

干预措施: latanoprost 0.005% ophthalmic solution (Drug)

结局指标

主要结局

Change From Baseline in Average Intraocular Pressure (IOP)

时间窗: Baseline, Month 3

IOP is a measurement of the fluid pressure inside the eye. For each patient, the IOP is the average of the two eyes. The average IOP is the average of the 08:00, 12:00 and 16:00 hour time points at each visit for each patient. A negative number change from Baseline indicates a reduction in average IOP (improvement).

次要结局

  • Absolute Difference Between Patient's Lowest IOP Reading at Baseline (Day 0) and the Corresponding IOP Reading(Baseline, Month 3)
  • Change From Baseline IOP(Baseline, Month 3)
  • Percentage of Patients Reaching a Predefined Target Pressure Threshold(Baseline, Month 3)
  • Absolute Difference Between Patient's Highest IOP Reading at Baseline (Day 0) and the Corresponding IOP Reading(Baseline, Month 3)

研究者

发起方
Allergan
申办方类型
Industry
责任方
Sponsor

相似试验